Natural Killer Cell Therapies - Pipeline Insight, 2021

DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Natural Killer Cell Therapies Understanding
Natural Killer Cell Therapies: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways

"Natural Killer Cell Therapies - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Natural Killer Cell Therapies pipeline landscape is provided which includes the disease overview and Natural Killer Cell Therapies treatment guidelines. The assessment part of the report embraces, in depth Natural Killer Cell Therapies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer Cell Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer Cell Therapies R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer Cell Therapies.

Natural Killer Cell Therapies Emerging Drugs Chapters
This segment of the Natural Killer Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Natural Killer Cell Therapies Emerging Drugs
Monalizumab: Innate Pharma
Monalizumab (also known as IPH2201) is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic NK and CD8 T lymphocytes. It is under development by Innate Pharma in Phase III stage for the treatment of Squamous Cell Carcinoma of the Head and Neck and in Phase II stage of development for the treatment of gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. It is in the Phase I stage of development for the treatment of advanced solid tumors and hematological malignancies.

NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
NKTR-214 is designed to grow specific cancer-killing T-cells and natural killer cell populations in the body that fight cancer is known as endogenous tumor-infiltering lymphocytes (TILs). NKTR-214 stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of these effector T cells.

ALT 803: ImmunityBio
ALT 803 is a novel IL-15 superagonist complex, with improved pharmacokinetic properties and enhanced anti-tumor activity compared to recombinant human IL-15. It has also shown to potently activate human effector NK cells and enhance antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-CD20 antibodies against human lymphoma cells in various tumor models. It is under development by Altor Bioscience Corporation and is currently in Phase II/III for Bladder Cancer. It is in Phase II stage for the treatment of Acute Myelogenous Leukemia (AML); Non-muscle Invasive Blood Cancer, in Phase I/II stage for the treatment of Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndromes (MDS); Multiple Myeloma; Advanced Pancreatic Cancer; Non-small Cell Lung Cancer and Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma. It is in Phase I stage for the treatment of Human Immunodeficiency virus (HIV) and Melanoma, Renal Cell, and Squamous Cell Head and Neck Cancer. It is developed by using IL-15 Protein Super agonist and Scaffold Technology and is administered by intravenous route.

ALECSAT: CytoVac
ALECSAT (Autologous Lymphoid Effector Cells Specific against Tumor-cells) is a therapy that supplements and strengthens the patients immune system so it can fight the cancer cells in the same way as the body originally should have reacted. Natural Killer Cells used, in the ALECSAT therapy attack, the cancer cells in several ways, as they can recognize more than one property of the cancer cells. ALECAST is being evaluated for breast cancer and newly diagnosed glioblastoma in Phase II.

PNK-007: Celularity
PNK-007 is a human umbilical cord blood-derived, culture-expanded natural killer cell therapy. The umbilical cord has CD34+ cells that are differentiated and expanded up to 50,000 fold over 35 days in a good manufacturing process (GMP) compliant facility to produce 12 billion cells that are 85% pure for NK cells without the use of a feeder cell line. These cells can be aliquoted and frozen for use at a later date. The CDK derived NK cells have substantial cytolytic activity against several human tumor cell lines, primary AML, and primary multiple myeloma cells. PNK-007 successfully completed pre-clinical studies for acute myeloid leukemia (AML) and multiple myeloma (MM) and is being evaluated in Phase I for the treatment of acute myeloid leukemia and Glioblastoma. PNK-007 is administered intravenously and developed by Cellular Therapeutics.
Further product details are provided in the report..

Natural Killer Cell Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Natural Killer Cell Therapies drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Natural Killer Cell Therapies
There are approx. 100+ key companies which are developing the therapies for Natural Killer Cell Therapies. The companies which have their Natural Killer Cell Therapies drug candidates in the most advanced stage, i.e. phase III include, Innate Pharma.

Phases
DelveInsights report covers around 140+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Natural Killer Cell Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intracranial
Intramuscular
Intratumoral
Intravenous
Intravenous
Parenteral
Subcutaneous
Molecule Type

Products have been categorized under various Molecule types such as
Small molecule
Antibodies
Beta Glucans
CAR-NK cell therapy
Cell Therapy
Gene therapies
Glycolipid
NK Cell therapy
NK T-Cell therapy
Oligodeoxyribonucleotides
Proteins
RNA
Stem cell therapies
Vaccines
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Natural Killer Cell Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Natural Killer Cell Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Natural Killer Cell Therapies drugs.

Natural Killer Cell Therapies Report Insights
Natural Killer Cell Therapies Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Natural Killer Cell Therapies Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Natural Killer Cell Therapies drugs?
How many Natural Killer Cell Therapies drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Natural Killer Cell Therapies?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Natural Killer Cell Therapies therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Natural Killer Cell Therapies and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
ImmunityBio
Five Prime Therapeutics
Innate Pharma
Nektar Therapeutics
Cantargia
CureTech
Dynavax
Cellid Company
Kiadis Pharma
Multimmune GmbH
CytoVac
XNK Therapeutics
NantKwest
Green Cross Corporation
HiberCell
Bristol-Myers Squibb
Innate Pharma
Affimed Therapeutics AG
Wugen
Abivax
Glycostem Therapeutics (IPD Therapeutic)
Synimmune
GT Biopharma
Bellicum Pharmaceuticals
Asclepius Technology Company Group
PersonGen BioTherapeutics (Suzhou)
Chongqing Sidemu Biotechnology
Artiva Biotherapeutics
NKMax
Acepodia
Allife Medical Science and Technology
Bright Path Biotherapeutics
Kuur Therapeutics (Formerly Cell Medica)

Key Products
ALT 803
Bemarituzumab
Monalizumab
NKTR-214 (Bempegaldesleukin)
Nidanilimab
Pidilizumab
SD-101
BVAC-C
PD-L1.t-haNK
K-NK002
Enkastim
ALECSAT
CellProtect
Nk-92
haNk
MG4101
Imprime PGG
Lirilumab
IPH4102
AFM-13
WU-NK-101
ABX196
AFM24
PNK-007
Allogeneic Natural Killer Cell Therapy (oNKord)
FLYSYN
KNK-ID-101
GTB-3550
CAR-NK cells
DF1001
DF-6002
NKG2D-ACE2 CAR-NK Cells
AB-101
SNK01
NKTR-225
Introduction
Executive Summary
Natural Killer Cell Therapies: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Natural Killer Cell Therapies DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Monalizumab: Innate Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
ALECSAT: CytoVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..

Early Stage Products (Phase I)
Comparative Analysis
CYAD-02: Celyad Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
CYT-501: Cytovia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..

Inactive Products
Comparative Analysis
Natural Killer Cell Therapies Key Companies
Natural Killer Cell Therapies Key Products
Natural Killer Cell Therapies- Unmet Needs
Natural Killer Cell Therapies- Market Drivers and Barriers
Natural Killer Cell Therapies- Future Perspectives and Conclusion
Natural Killer Cell Therapies Analyst Views
Natural Killer Cell Therapies Key Companies
Appendix

List Of Tables

Table 1 Total Products for Natural Killer Cell Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Natural Killer Cell Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Natural Killer Cell Therapies - Pipeline Insight, 2021

DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the

USD 3000 View Report

Natural Cytotoxicity Triggering Receptor 1 (Lymphocyte Antigen 94 Homolog or NK Cell Activating Receptor or Natural Killer Cell p46 Related Protein or CD335 or NCR1) - Drugs in Development, 2021

Natural Cytotoxicity Triggering Receptor 1 (Lymphocyte Antigen 94 Homolog or NK Cell Activating Receptor or Natural Killer Cell p46 Related Protein or CD335 or NCR1) - Drugs in Development, 2021Natural

USD 3000 View Report

Cells Expressing NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2D Activating NK Receptor or CD314 or NKG2D or KLRK1) - Drugs in Development, 2021

Cells Expressing NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2D Activating NK Receptor or CD314

USD 3000 View Report

NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2 D Activating NK Receptor or CD314 or KLRK1) - Drugs in Development, 2021

NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2 D Activating NK Receptor or CD314 or

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available